By SaiyanMed Research Team · Updated 5 November 2026 · For in-vitro research use only
RESEARCH USE ONLY — PROFESSIONAL LABORATORY USE. This article is for qualified laboratory personnel carrying out in-vitro assays or institutionally approved laboratory animal studies. It is not a home-use, personal-use, human-use, or veterinary-use guide. The information below must not be used as an administration, formulation, reconstitution, or dosing plan. VK2735 is an investigational compound developed by Viking Therapeutics. Its safety and efficacy have not been approved for marketing by the FDA or other regulators for any indication. Clinical trial results are summarized here as published research / company IR data, not as medical advice. SaiyanMed does not list a VK2735 product SKU on this page (catalog / product-sitemap check 2026-11-05).
Quick answer
VK2735 is Viking Therapeutics’ investigational dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The company is developing both a once-weekly subcutaneous formulation and a once-daily oral tablet formulation for metabolic / obesity research programs [Viking IR 2026-10-14; Viking pipeline].
Public late-stage work (as of this draft) includes:
| Program | Formulation | Phase | Headline public status |
|---|---|---|---|
| VANQUISH-1 / VANQUISH-2 | Subcutaneous, weekly | Phase 3 | Fully enrolled per Viking IR (2026-10-14); CT.gov ACTIVE_NOT_RECRUITING [NCT07104500; NCT07104383] |
| SUNRISE-1 / SUNRISE-2 | Oral, once daily | Phase 3 | Viking announced initiation 2026-10-14; CT.gov listings NOT_YET_RECRUITING with estimated starts ~Nov 2026 [NCT07868835; NCT07868939; Viking IR 2026-10-14] |
| VENTURE (SC) / VENTURE-Oral | SC weekly / oral daily | Phase 2 (completed) | Positive toplines disclosed by Viking (13-week weight endpoints) [Viking pipeline; Viking IR 2026-10-14] |
VK2735 is not the same molecule as:
| Peer (research context) | Public MoA headline | Why it is different |
|---|---|---|
| Tirzepatide | Dual GIP / GLP-1 (approved medicines exist) | Same class headline, different sponsor molecule / programs — do not treat RUO powder as Zepbound/Mounjaro |
| Retatrutide | Unimolecular GIP / GLP-1 / glucagon triple | Adds glucagon as a third headline pathway |
| Survodutide | Dual glucagon / GLP-1 | No GIP headline; different sponsor (BI/Zealand) |
| Zenagamtide | Unimolecular GLP-1 + amylin | Amylin pathway, not GIP dual |
| Semaglutide | Mono GLP-1 | No GIP co-agonism as public design |
No INN is treated as settled public naming on this hub — sponsor materials use the development code VK2735.
Dual GIP / GLP-1 pharmacology
What “dual GIP/GLP-1 agonist” means in sponsor framing
Viking describes VK2735 as a dual agonist of the GLP-1 and GIP receptors — the same broad receptor-class headline used for approved dual incretin medicines such as tirzepatide in Viking’s own educational “About” copy [Viking IR 2026-10-14; Viking pipeline]. ClinicalTrials.gov intervention text for VANQUISH likewise calls VK2735 a “peptide GLP-1 and GIP dual agonist” administered once weekly in the SC program [NCT07104500].
| Approach | Example | Public receptor headline |
|---|---|---|
| Mono GLP-1 RA | Semaglutide | GLP-1R |
| Dual GIP/GLP-1 | Tirzepatide; VK2735 | GIPR + GLP-1R |
| Dual glucagon/GLP-1 | Survodutide | GCGR + GLP-1R |
| Triple GIP/GLP-1/glucagon | Retatrutide | GIPR + GLP-1R + GCGR |
| Dual GLP-1/amylin (unimolecular) | Zenagamtide | GLP-1R + amylin receptors |
Hedges that belong in any careful research summary
- In-vitro potency rankings are assay-specific. This hub does not invent EC50 tables.
- Clinical % weight-loss figures are trial-reported outcomes, not a reconstitution recipe or a ranking of “which vial to buy for patients.”
- Sharing a GIP/GLP-1 dual class headline with tirzepatide does not make VK2735 interchangeable with approved tirzepatide products — or with grey-market “dual agonist” powders.
- Cross-trial % weight loss is not a clinical ranking versus tirzepatide, retatrutide, survodutide, or zenagamtide.
Related SaiyanMed class reading (tirzepatide-adjacent): Tirzepatide vs semaglutide · Tirzepatide mechanism · Tirzepatide and semaglutide · RUO listing context tirzepatide product (separate SKU — not VK2735).
Subcutaneous VANQUISH Phase 3
Milligram figures below are trial-reported dose labels from Viking IR and ClinicalTrials.gov. They are not laboratory reconstitution or personal titration instructions.
| Trial | NCT | Population (high-level) | Status (public) | Design notes |
|---|---|---|---|---|
| VANQUISH-1 | NCT07104500 | Obesity / overweight without T2D (+ ≥1 weight-related comorbidity if overweight) | CT.gov ACTIVE_NOT_RECRUITING; Viking IR: fully enrolled ≈4,500 | 78-week SC weekly; arms 7.5 / 12.5 / 17.5 mg or placebo [Viking IR 2026-10-14; NCT07104500] |
| VANQUISH-2 | NCT07104383 | Obesity / overweight with T2D | CT.gov ACTIVE_NOT_RECRUITING; Viking IR: fully enrolled ≈1,000 (CT.gov estimated enrollment 1,100) | Same weekly SC dose labels vs placebo; 78 weeks [Viking IR 2026-10-14; NCT07104383] |
Primary endpoint theme (both): percent change in body weight from baseline after 78 weeks vs placebo [NCT07104500; NCT07104383].
Secondaries (registry): proportions achieving ≥5%, ≥10%, ≥15%, ≥20% weight reduction at week 78.
Gap flag: No VANQUISH Phase 3 topline efficacy numbers are cited in this hub — none were available as primary IR readouts for this draft date. Prefer Viking IR / peer-reviewed publication when they appear.
Oral SUNRISE Phase 3 (new)
On 14 October 2026, Viking announced initiation of the SUNRISE Phase 3 program for oral VK2735 [Viking IR 2026-10-14].
| Trial | NCT | Population (high-level) | Enrollment target | Duration / schedule | Dose labels (IR) |
|---|---|---|---|---|---|
| SUNRISE-1 | NCT07868835 | Obese or overweight without T2D (+ comorbidity if overweight) | 560 each | 68 weeks; once-daily oral | 27.5 / 35 / 55 mg or placebo |
| SUNRISE-2 | NCT07868939 | Obese or overweight with T2D | 560 each | 68 weeks; once-daily oral | Same four-arm theme |
Primary endpoint (IR + registry framing): percent change in body weight vs placebo at 68 weeks. Secondaries include ≥5 / ≥10 / ≥15 / ≥20% responder rates [Viking IR 2026-10-14].
Registry status note (gap): As of CT.gov fetch 2026-11-05, both SUNRISE records show NOT_YET_RECRUITING with estimated starts around November 2026, while Viking’s 14 Oct IR uses “initiation” language. Treat IR as the corporate announcement and CT.gov as the registry snapshot — do not invent first-patient-in dates.
Viking’s CEO framing in the same IR positions oral VK2735 as potentially useful for induction or maintenance settings and states it is “the most advanced oral dual GLP-1/GIP agonist in clinical development” — that is sponsor positioning language, not an independent ranking or a SaiyanMed product claim [Viking IR 2026-10-14].
Maintenance dosing trial (high-level only): The same IR notes an ongoing oral maintenance dosing trial and corrects a prior 6 Oct 2026 release that wrongly said “weekly oral” — corrected options include daily oral, monthly SC, every-other-week SC, or placebo. No efficacy numbers and no separate NCT ID are promoted here without a dedicated registry fetch [Viking IR 2026-10-14].
Phase 2 oral VENTURE signals
Every figure below is a trial-reported outcome as restated in Viking’s 2026-10-14 IR summarizing the Phase 2 VENTURE-Oral study. None of it is a dosing schedule or product claim for research vials.
From Viking IR [Viking IR 2026-10-14] (study topline originally announced in 2025 per that release):
| Endpoint (13 weeks; as stated) | Oral VK2735 | Placebo |
|---|---|---|
| Mean body-weight % change from baseline (up to…) | −12.2% | — (placebo-adjusted significance claimed for doses >15 mg from Week 1 onward) |
| ≥5% weight loss (up to…) | 97% | 10% |
| ≥10% weight loss (up to…) | 80% | 5% |
Additional sponsor language from the same IR:
- Weight loss was described as progressive through Week 13 with no evidence of a plateau.
- 98% of reported drug-related TEAEs characterized as mild or moderate; GI events most common, generally early, consistent with dual GLP-1/GIP class expectations.
- Progressive dose escalation in 30 mg increments is mentioned as a trial tolerability theme — not a lab or personal titration recipe.
Registry pointer: Phase 2 oral study listing NCT06828055 (VENTURE Oral Dosing; completed per CT.gov). Prefer IR for the % tables above; expand arm-level detail only from primary IR/poster PDFs when fetched.
Phase 2 subcutaneous VENTURE (pipeline primary — context)
Viking’s pipeline page summarizes the SC Phase 2 VENTURE trial (13 weeks; enrollment increased to 176) [Viking pipeline; registry NCT06068946]:
| Endpoint (13 weeks; as stated on pipeline) | VK2735 (up to…) | Placebo |
|---|---|---|
| Mean body-weight % change from baseline | −14.7% | — |
| Placebo-adjusted mean weight % change | −13.1% | — |
| ≥10% weight loss | 88% | 4% |
Discontinuation ~13% VK2735-treated vs 14% placebo; majority of drug-related TEAEs mild/moderate (92%); nausea 43% vs 20% placebo; vomiting 18% vs 0% (pipeline narrative). ObesityWeek 2024 PK subset language: majority of weight loss maintained 4 weeks after last dose — used by Viking to support monthly maintenance feasibility hypotheses, not as a completed Ph3 maintenance label [Viking pipeline].
SC vs oral research formulations
| Dimension | Subcutaneous VK2735 | Oral VK2735 |
|---|---|---|
| Public schedule in Ph3 | Once weekly SC (VANQUISH) | Once daily tablet (SUNRISE) |
| Ph3 duration | 78 weeks | 68 weeks |
| Ph3 dose labels (IR / CT.gov) | 7.5 / 12.5 / 17.5 mg vs placebo | 27.5 / 35 / 55 mg vs placebo |
| Ph2 signal cited here | VENTURE SC up to −14.7% @ 13 wk [pipeline] | VENTURE-Oral up to −12.2% @ 13 wk [IR 2026-10-14] |
| Same active? | Same development code VK2735; different formulation / exposure path — do not assume bioequivalence of grey-market powders to either clinical product | |
Compliance: Different milligram labels across oral vs SC arms are not interchangeable conversion factors for laboratory reconstitution.
Positioning vs tirzepatide / retatrutide / peers (mechanism, not “better”)
Cross-trial % weight loss is not a clinical ranking. Populations, estimands, durations, and background therapies differ.
| Dimension | VK2735 | Tirzepatide | Retatrutide | Survodutide | Zenagamtide |
|---|---|---|---|---|---|
| Public MoA | Dual GIP + GLP-1 | Dual GIP + GLP-1 | Triple GIP + GLP-1 + glucagon | Dual glucagon + GLP-1 | Dual GLP-1 + amylin |
| Sponsor | Viking | Eli Lilly (approved products) | Eli Lilly (investigational) | BI (Zealand-origin) | Novo Nordisk |
| Oral dual GIP/GLP-1 Ph3? | SUNRISE oral Ph3 initiated per Viking IR 2026-10-14 | Oral / injectable products exist in approved settings (separate medicines) | Not this molecule | Injectable Ph3 focus | Oral + SC zenagamtide programs (different MoA) |
| SaiyanMed SKU (this draft) | None | Soft-link product exists | Soft-link product exists | None | Educational / wait COA |
For class literacy: What Is Retatrutide? · What Is Survodutide? · What Is Zenagamtide (Amycretin)? · Tirzepatide vs semaglutide.
Research / analytical identity notes
Why a vial label is not clinical identity
“VK2735,” informal dual-agonist nicknames, or “oral tablet equivalent” stickers on a lyophilized powder do not prove equivalence to Viking’s clinical-trial drug product (SC or oral). Dual-agonist peptides can fail by wrong sequence/length, incomplete modification, isomer content, aggregation, residual solvents, or simple mislabeling. Cake appearance is not an analytical method.
Stock status on SaiyanMed
No VK2735 catalog SKU is claimed. Educational hub only (site product/post sitemap + catalog check 2026-11-05: no matching product or post URL). Any future RUO listing would require supplier COA review and explicit go-ahead — do not assume inventory from this article.
Minimum COA packet (if a research lot is ever listed)
| Item | Why it matters |
|---|---|
| Lot-matched COA | Must match the vial lot — not a “representative” PDF |
| RP-HPLC / UPLC purity + chromatogram | Area-% under a stated method; inspect shoulders |
| Intact-mass LC-MS | Observed vs theoretical mass for the intact modified peptide |
| Peptide content / counterion / water | Separates peptide mass from salt and residual solvent |
| Traceability | Manufacture/test dates, method IDs, lab identity |
Handling themes (no recipes)
Lyophilized peptides are commonly stressed by moisture, heat, light, and repeated freeze–thaw after reconstitution. Follow the batch COA and your institution’s validated procedures. This article does not provide diluent volumes, concentrations, injection instructions, titration schedules, or study protocols.
Myth vs evidence
| Myth | Evidence-based correction |
|---|---|
| “VK2735 is just tirzepatide / Zepbound under another name.” | Same class headline (dual GIP/GLP-1); different sponsor molecule and trial programs [Viking IR 2026-10-14]. |
| “Same as retatrutide.” | Retatrutide adds glucagon as a third pathway [retatrutide hub]. |
| “Same as survodutide.” | Survodutide is glucagon/GLP-1 dual, not GIP dual [survodutide hub]. |
| “Same as zenagamtide / amycretin.” | Zenagamtide is GLP-1 + amylin [zenagamtide hub]. |
| “Oral Ph3 means it is approved as a pill.” | SUNRISE is investigational Phase 3; no marketing approval is claimed here. |
| “−12.2% oral @ 13 weeks equals VANQUISH Ph3 results.” | Different phase, duration, formulation, and population — do not merge. |
| “RUO vials are for personal weight loss.” | Explicitly out of scope. |
Glossary
- VK2735: Viking investigational dual GIP/GLP-1 receptor agonist peptide (SC + oral formulations in development).
- GIP / GIPR: Glucose-dependent insulinotropic polypeptide / its receptor.
- GLP-1 / GLP-1R: Glucagon-like peptide-1 / its receptor.
- VANQUISH: Phase 3 SC weekly program (VANQUISH-1 without T2D; VANQUISH-2 with T2D).
- SUNRISE: Phase 3 oral daily program (SUNRISE-1 without T2D; SUNRISE-2 with T2D).
- VENTURE / VENTURE-Oral: Phase 2 SC and oral studies that informed Ph3 designs.
- RUO: Research Use Only — not for human or veterinary administration.
- COA: Certificate of Analysis for a specific lot.
FAQ
What is VK2735?
VK2735 is Viking Therapeutics’ investigational dual GIP/GLP-1 receptor agonist peptide, developed in both subcutaneous weekly and oral daily formulations and studied in Phase 2 VENTURE programs and Phase 3 VANQUISH (SC) / SUNRISE (oral) programs [Viking IR 2026-10-14; Viking pipeline].
Is VK2735 FDA-approved?
No. It remains investigational; efficacy and safety have not been established for marketing.
What is new about SUNRISE?
Viking announced initiation of oral Phase 3 SUNRISE-1 and SUNRISE-2 on 2026-10-14 (68 weeks; ~560 participants each; once-daily oral dose labels 27.5 / 35 / 55 mg or placebo) [Viking IR 2026-10-14; NCT07868835; NCT07868939].
What did VENTURE-Oral show?
Per Viking’s 2026-10-14 IR restating the Phase 2 oral topline: up to −12.2% mean weight change from baseline at 13 weeks, with up to 97% / 80% achieving ≥5% / ≥10% weight loss vs 10% / 5% on placebo [Viking IR 2026-10-14].
How does VK2735 differ from tirzepatide?
Both are publicly framed as dual GIP/GLP-1 agonists. Tirzepatide has approved medicine products; VK2735 is investigational with Viking-owned SC and oral Ph3 programs. They are not the same drug product [Viking IR 2026-10-14].
How does it differ from retatrutide?
Retatrutide is a triple GIP/GLP-1/glucagon agonist [retatrutide hub].
Does SaiyanMed sell VK2735?
No SKU is claimed on this page (catalog check 2026-11-05). This hub is research education only.
Can I use these trial percentages as a personal protocol?
No. Trial figures are published research / IR data under specific protocols. This page provides no dosing, reconstitution, or titration guidance.
Sources & further reading
- Viking Therapeutics IR — oral Ph3 SUNRISE initiation (2026-10-14): https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity
- PR Newswire mirror: https://www.prnewswire.com/news-releases/viking-therapeutics-announces-initiation-of-vk2735-oral-phase-3-clinical-program-in-patients-with-obesity-302907849.html
- Viking pipeline — VK2735: https://vikingtherapeutics.com/pipeline/vk2735/
- VANQUISH-1: https://clinicaltrials.gov/study/NCT07104500
- VANQUISH-2: https://clinicaltrials.gov/study/NCT07104383
- SUNRISE-1: https://clinicaltrials.gov/study/NCT07868835
- SUNRISE-2: https://clinicaltrials.gov/study/NCT07868939
- VENTURE SC Ph2: https://clinicaltrials.gov/study/NCT06068946
- VENTURE Oral Ph2: https://clinicaltrials.gov/study/NCT06828055
Internal: What Is Retatrutide? · What Is Survodutide? · What Is Zenagamtide? · Tirzepatide vs semaglutide · Tirzepatide mechanism